Effect of GSK1120212, GSK2118436 + Panitumumab in colorectal cancer

• Research type

  Research Study

• Full title

  An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the anti-EGFR Antibody Panitumumab in Combination in Subjects with BRAF- mutation V600E Positive Colorectal Cancer and in Subjects with CRC with Secondary Resistance to Prior Anti-EGFR Therapy

• IRAS ID

  132540

• Contact name

  Gary Middleton

• Contact email

  g.middleton@bham.ac.uk

• Sponsor organisation

  GlaxoSmithKline Research and Development

• Eudract number

  2012-004802-81

• ISRCTN Number

  n/a

• REC name

  South West - Cornwall & Plymouth Research Ethics Committee

• REC reference

  13/SW/0261

• Date of REC Opinion

  25 Nov 2013

• REC opinion

  Further Information Favourable Opinion